However, because fluoxetine is not a specific inhibitor of TREK–1, specific TREK–1 inhibitors, sodium ions inhibitors, and calcium ion inhibitors are required to demonstrate whether particular TREK–1 inhibition protects from bleomycin pulmonary fibrosis. The gene discussed is KCNK2; the disease is pulmonary fibrosis.